published meta-analysis   sensitivity analysis   studies

chloroquine and derivatives in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsFACCT Trial, 2021 0.69 [0.28; 1.68] 0.69[0.28; 1.68]FACCT Trial, 202110%254NAnot evaluable deathsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52] FACCT Trial, 2021 0.96 [0.44; 2.08] 1.10[0.58; 2.08]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, FACCT Trial, 202120%586moderatenot evaluable clinical deteriorationdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12] 1.21[0.69; 2.12]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 202010%332NAnot evaluable clinical improvement (14-day)detailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44] 0.83[0.47; 1.44]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 202010%448NAnot evaluable clinical improvement (time to event analysis only)detailed resultsFACCT Trial, 2021 0.85 [0.62; 1.16] 0.85[0.62; 1.16]FACCT Trial, 202110%254NAnot evaluable hospital dischargedetailed resultsFACCT Trial, 2021 0.88 [0.64; 1.21] 0.88[0.64; 1.21]FACCT Trial, 202110%254NAnot evaluable ICU admissiondetailed resultsFACCT Trial, 2021 1.42 [0.79; 2.55] 1.42[0.79; 2.55]FACCT Trial, 202110%254NAnot evaluable adverse eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65] 0.88[0.29; 2.65]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 202010%332NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-03-29 07:58 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 508,656,657,832 - roots T: 290